Lundbeck EVP aims for phase III next year after new PTSD data
Although Lundbeck only partly succeeded in a new phase II study with a combination therapy against PTSD, the executive vice president for Research and Development still sees a potential in the indication and expects to initiate phase III next year.
Lundbeck is aiming for phase III in 2019 after the Danish drug group and its Japanese partner Otsuka received phase II data for a trial combining the drug brexpiprazole and Pfizer's Zoloft for treatment of Post-Traumatic Stress Disorder (PTSD).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Here are the challenges awaiting the new CEO at Lundbeck
For abonnenter
